AllianceBernstein’s Corvus Pharmaceuticals CRVS Stock Holding History

AllianceBernstein’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.32M	Buy	90,420 +28,680	+46%	+$398K	﹤0.01%	2257
2026 Q1	$475K	Buy	61,740 +44,620	+261%	+$712K	﹤0.01%	2664
2025 Q4	$132K	Hold	17,120	–	–	﹤0.01%	3145
2025 Q3	$126K	Hold	17,120	–	–	﹤0.01%	3155
2025 Q2	$68.5K	Buy	+17,120	New	+$62.3K	﹤0.01%	3195
2019 Q2	–	Sell	-16,100	Closed	-$65K	–	3155
2019 Q1	$65K	Hold	16,100	–	–	﹤0.01%	3068
2018 Q4	$59K	Hold	16,100	–	–	﹤0.01%	3046
2018 Q3	$138K	Buy	16,100 +800	+5%	+$8K	﹤0.01%	3045
2018 Q2	$168K	Buy	15,300 +1,700	+13%	+$19K	﹤0.01%	3005
2018 Q1	$157K	Hold	13,600	–	–	﹤0.01%	2908
2017 Q4	$141K	Sell	13,600 -900	-6%	-$11.5K	﹤0.01%	2928
2017 Q3	$231K	Hold	14,500	–	–	﹤0.01%	2871
2017 Q2	$175K	Buy	+14,500	New	+$155K	﹤0.01%	3022

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

AllianceBernstein's CRVS Position: Q2 2026 in Review

AllianceBernstein increased its Corvus Pharmaceuticals (CRVS) stake by 46% in Q2 2026, buying an estimated $398K and bringing the position to 90,420 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2257.

AllianceBernstein first reported a position in CRVS in Q2 2017 and has held it in 13 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

AllianceBernstein held 90,420 shares of Corvus Pharmaceuticals worth $1.32M as of Q2 2026.
AllianceBernstein bought 28,680 Corvus Pharmaceuticals shares in Q2 2026, an estimated $398K.
Corvus Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2257 holding.
AllianceBernstein first reported a position in Corvus Pharmaceuticals in Q2 2017 and has held it in 13 quarters since.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.